Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Non-Current Deffered Revenue (2017 - 2022)

Denali Therapeutics has reported Non-Current Deffered Revenue over the past 6 years, most recently at $479000.0 for Q4 2022.

  • Quarterly Non-Current Deffered Revenue fell 85.9% to $479000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $479000.0 through Dec 2022, down 85.9% year-over-year, with the annual reading at $479000.0 for FY2022, 85.9% down from the prior year.
  • Non-Current Deffered Revenue was $479000.0 for Q4 2022 at Denali Therapeutics, down from $3.4 million in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $57.4 million in Q4 2018 and troughed at $479000.0 in Q4 2022.
  • The 5-year median for Non-Current Deffered Revenue is $31.3 million (2021), against an average of $28.7 million.
  • Year-over-year, Non-Current Deffered Revenue skyrocketed 811.19% in 2018 and then tumbled 89.15% in 2022.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $57.4 million in 2018, then fell by 23.71% to $43.8 million in 2019, then tumbled by 46.69% to $23.3 million in 2020, then crashed by 85.43% to $3.4 million in 2021, then plummeted by 85.9% to $479000.0 in 2022.
  • Per Business Quant, the three most recent readings for DNLI's Non-Current Deffered Revenue are $479000.0 (Q4 2022), $3.4 million (Q2 2022), and $3.4 million (Q1 2022).